The Zacks Analyst Blog Highlights: Sanofi, Regeneron Pharmaceuticals, United Therapeutics, Medivation and Idenix Pharmaceuticals

Feb 21, 2014, 09:30 ET from Zacks Investment Research, Inc.

CHICAGO, Feb. 21, 2014 /PRNewswire/ -- announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Sanofi (NYSE: SNY-Free Report), Regeneron Pharmaceuticals, Inc.  (Nasdaq: REGN-Free Report), United Therapeutics Corporation (Nasdaq: UTHR-Free Report), Medivation, Inc. (Nasdaq: MDVN-Free Report) and Idenix Pharmaceuticals Inc. (Nasdaq: IDIX-Free Report).


Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Thursday's Analyst Blog:

3 Biotech Stocks to Bet On

Biotech companies have been attracting a lot of attention with big pharma players resorting to biopharmaceuticals to bolster their beleaguered pipelines. For example, Sanofi (NYSE: SNY-Free Report) is planning to increase its stake in Regeneron Pharmaceuticals, Inc.  (Nasdaq: REGN-Free Report). Merger and acquisition (M&A) and licensing activities in this segment have increased significantly with pharma companies targeting biotech stocks that have attractive pipeline candidates or technology that can be used for the development of novel therapeutics.

Additionally, the industry has been in the news this year with several companies going public.

The earnings season is on its last leg with several biotech companies having already released their fourth quarter numbers and guidance for 2014. However, it is not too late to join the biotech bandwagon. In fact, it is a good idea to zero in on a handful of biotech stocks that are poised to beat earnings estimates this quarter. An earnings beat should help these stocks gain investor confidence and show favorable price movement.

How to Pick?

Given a large number of industry participants, pinpointing stocks that have the potential to beat estimates could appear to be a daunting task. But our proprietary methodology makes it fairly simple. One way to narrow down the list of choices this earnings season is by looking at stocks that have the combination of a favorable Zacks Rank – Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) – and a positive Zacks Earnings ESP (Expected Surprise Prediction).

Earnings ESP is our proprietary methodology for identifying stocks that have high chances of surprising in their next earnings announcement. It shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate.

Our research shows that for stocks with this combination, the chance of a positive earnings surprise is as high as 70%.

Below are three biotech stocks we believe are best positioned to stand out this earnings season.

United Therapeutics Corporation (Nasdaq: UTHR-Free Report), based in Silver Spring, Md., is a Zacks Rank #2 (Buy) stock with an Earnings ESP of +15.39%. The Zacks Consensus Estimate for the fourth quarter is $1.69.

United Therapeutics is a biotechnology company focused on the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases. The company has delivered positive earnings surprises in two of the last four quarters.

Key growth driver Remodulin should continue with its strong performance in the fourth quarter. Other products like Tyvaso and Adcirca are also expected to do well.

-United Therapeutics is scheduled to announce its fourth quarter 2013 financial results before the opening bell on Feb 25.

Medivation, Inc. (Nasdaq: MDVN-Free Report) is a Zacks Rank #2 stock with an Earnings ESP of +36.36%. The Zacks Consensus Estimate for the fourth quarter stands at a loss of 11 cents. The company has a solid track record of delivering positive surprises with an average beat of 32.57% in the last four quarters. The company is expected to beat expectations in the fourth quarter as well.

The San Francisco, Calif.-based biopharmaceutical company is engaged in the development and commercialization of therapies targeting serious diseases for which there are limited treatment options.  

The company's sole marketed product - Xtandi is expected to continue with its impressive performance in the fourth quarter.

Medivation will be reporting fourth quarter 2013 results after market close on Feb 27.

Idenix Pharmaceuticals Inc. (Nasdaq: IDIX-Free Report), based in Cambridge, Mass., is focused on the discovery and development of therapies for the treatment of patients suffering from hepatitis C virus (HCV). The stock carries a Zacks Rank #2, with an Earnings ESP of +13.64%. The Zacks Consensus Estimate for the fourth quarter is a loss of 22 cents.

Although the surprise history for the stock has been unimpressive in the past, it is poised for a beat this fourth quarter. The company's restructuring initiative should help contain some of its losses.

Idenix is expected to report fourth quarter 2013 earnings on Feb 24.

Bottom Line

While a number of biotech companies are seeing improvements in their financial results, some challenges in the form increasing competition remain. The companies are nevertheless looking for better strategies to emerge as winners. A sneak peek at the space for some outperformers, backed by a solid Zacks Rank and a positive Zacks Earnings ESP, could be a great idea for investors to gain from this earnings season.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on SNY - FREE

Get the full Report on REGN - FREE

Get the full Report on UTHR - FREE

Get the full Report on MDVN - FREE

Get the full Report on IDIX - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

SOURCE Zacks Investment Research, Inc.